Vertex Pharmaceuticals Inc / Ma
A global biotech developing transformative medicines for serious diseases, Vertex Pharmaceuticals is best known for its cystic fibrosis franchise — KALYDECO, ORKAMBI, SYMDEKO, TRIKAFTA, and ALYFTREK — which treats most people with CF in key Western markets. The company also makes CASGEVY, a CRISPR gene-editing therapy for sickle cell disease and beta thalassemia, and JOURNAVX, a non-opioid pain signal inhibitor for acute pain. Its pipeline targets kidney disease, chronic pain, and type 1 diabetes.
Granted 2.33M · Sold 2.37M
Granted 326.4K · Sold 309.0K
Granted 275.7K · Sold 76.6K
Granted 646.7K · Sold 578.9K
Granted 180.5K · Sold 137.7K
Granted 435.5K · Bought 20.0K · Sold 186.7K
Granted 99.6K · Sold 74.1K
Granted 1.81M · Sold 1.85M
Granted 143.3K · Sold 72.5K
Granted 282.4K · Sold 222.2K
Granted 1.34M · Bought 1.0K · Sold 1.19M
Granted 1.02M · Sold 831.0K
Granted 72.2K · Bought 4.0K · Sold 19.1K
Granted 22.7K · Sold 21.9K
Granted 57.1K · Sold 3.8K
Granted 230.0K · Sold 230.0K
Granted 172.2K · Sold 60.6K
Granted 154.2K · Sold 54.1K
Granted 319.3K · Bought 163.7K · Sold 389.9K
Granted 149.6K · Sold 117.3K
Granted 114.3K · Sold 89.4K
Granted 35.5K · Sold 8.8K
Granted 3.14M · Bought 2.6K · Sold 2.82M
Granted 51.5K · Sold 22.6K
Granted 593.1K · Sold 473.1K
Granted 300.4K · Sold 239.5K
Granted 227.3K · Sold 377.4K
Granted 73.9K · Sold 35.3K
Granted 50.4K · Sold 50.0K
Granted 10.2K · Sold 328
Granted 59.3K · Sold 50.0K
Granted 153.6K · Sold 138.0K
Granted 38.8K · Bought 6.5K
Granted 8.9K · Sold 14.0K
Granted 54.0K · Sold 25.0K
Granted 144.9K · Sold 72.3K
Granted 45.0K · Sold 17.1K
Granted 11.8K · Sold 10.0K
Granted 14.1K · Sold 1.9K
Granted 194.4K · Bought 5.0K · Sold 187.2K
Sold 6.0K
Granted 15.5K · Sold 10.4K
Granted 60.0K · Sold 59.6K
Granted 390.7K · Sold 377.7K
Granted 57.5K · Sold 57.5K
Granted 7.3K
Granted 2.6K · Sold 6.3K
Granted 25.4K · Sold 11.4K
Granted 137.1K · Sold 130.6K
Granted 9.8K · Sold 2.7K
Granted 63.5K · Sold 58.6K
Granted 8.6K
Granted 76.9K · Sold 73.3K
Granted 2.2K
Granted 2.5K
Granted 4.5K
Granted 1.1K
Granted 10.0K · Bought 1.1K · Sold 10.0K
Granted 133.6K · Bought 1.1K · Sold 125.0K
Granted 27.5K · Sold 27.5K
| Insider | Stake change | Holds now | Granted / vested | Bought | Sold |
|---|---|---|---|---|---|
| Boger Joshua SDirector · 1220 transactions | — | 918.1Kas of Jun 2017 | 2.33M | — | 2.37M |
| Boger Kenneth SSVP & Chief Legal Officer · 56 transactions | — | 413.6Kas of Sep 2011 | 326.4K | — | 309.0K |
| Emmens MatthewDirector · 9 transactions | — | 200.9Kas of Nov 2012 | 275.7K | — | 76.6K |
| Mueller PeterEVP, Global R&D, CSO · 191 transactions | — | 170.7Kas of Jun 2014 | 646.7K | — | 578.9K |
| Alam John JEVP, Med. Dev. Group & CMO · 99 transactions | — | 146.2Kas of Oct 2008 | 180.5K | — | 137.7K |
| Kewalramani ReshmaCEO & President, Director · 136 transactions | — | 106.0K | 435.5K | 20.0K | 186.7K |
| Hartmann Victor AEVP, Strategic & Corp. Devlp. · 20 transactions | — | 99.5Kas of Jun 2007 | 99.6K | — | 74.1K |
| Smith Ian FEVP, COO · 239 transactions | — | 75.4Kas of Jul 2018 | 1.81M | — | 1.85M |
| Horton Kenneth LEVP & Chief Legal Officer · 16 transactions | — | 72.4Kas of Nov 2014 | 143.3K | — | 72.5K |
| Chodakewitz JeffreyEVP GMDA, CMO · 123 transactions | — | 72.4Kas of Feb 2018 | 282.4K | — | 222.2K |
| Sachdev AmitEVP Chief Patient & Ext Af Off · 398 transactions | — | 65.8K | 1.34M | 1.0K | 1.19M |
| Arbuckle Stuart AEVP, COO · 395 transactions | — | 63.5Kas of Jul 2025 | 1.02M | — | 831.0K |
| Graves KurtEVP, Chief Commercial Officer · 39 transactions | — | 60.5Kas of Oct 2009 | 72.2K | 4.0K | 19.1K |
| Brum Lynne HVP, Strategic Communications · 41 transactions | — | 59.8Kas of May 2006 | 22.7K | — | 21.9K |
| Lewis-Hall Freda CEVP, Medicines Development · 7 transactions | — | 53.3Kas of Mar 2009 | 57.1K | — | 3.8K |
| Collinson Stuart JDirector · 15 transactions | — | 53.3Kas of Dec 2006 | 230.0K | — | 230.0K |
| Wagner Charles F JrEVP, CO & FO · 94 transactions | — | 47.0K | 172.2K | — | 60.6K |
| Tatsis OuraniaEVP, Chief Reg. & Quality Off. · 142 transactions | — | 46.8K | 154.2K | — | 54.1K |
| Sachs Bruce IDirector · 145 transactions | — | 45.0Kas of Aug 2025 | 319.3K | 163.7K | 389.9K |
| Pace Megan ESVP, Corp. Communications · 37 transactions | — | 43.4Kas of Nov 2014 | 149.6K | — | 117.3K |
| Stamoulis ChristianaSVP, Corp Strategy & Bus Devlp · 17 transactions | — | 41.8Kas of Jul 2013 | 114.3K | — | 89.4K |
| Garrison Richard CSVP and Catalyst · 38 transactions | — | 38.8Kas of May 2009 | 35.5K | — | 8.8K |
| Leiden Jeffrey MExecutive Chairman, Director · 290 transactions | — | 35.2K | 3.14M | 2.6K | 2.82M |
| Connolly ThomasSVP, Human Resources · 38 transactions | — | 34.5Kas of Dec 2014 | 51.5K | — | 22.6K |
| Altshuler DavidEVP, Chief Scientific Officer · 336 transactions | — | 34.5K | 593.1K | — | 473.1K |
| Parini MichaelEVP, Chief Adm, Leg & BD Off · 234 transactions | — | 33.2Kas of Feb 2021 | 300.4K | — | 239.5K |
| Wysenski NancyEVP, Chief Commercial Officer · 19 transactions | — | 32.6Kas of May 2012 | 227.3K | — | 377.4K |
| Sanna BastianoEVP, Cell & Genetic Therapies · 87 transactions | — | 32.0Kas of May 2023 | 73.9K | — | 35.3K |
| Sanders Charles ADirector · 53 transactions | — | 29.7Kas of May 2009 | 50.4K | — | 50.0K |
| Howton David TSVP & Chief Legal Officer · 2 transactions | — | 29.6Kas of Feb 2012 | 10.2K | — | 328 |
| Young William DDirector · 14 transactions | — | 29.3Kas of Jan 2020 | 59.3K | — | 50.0K |
| Kelly LisaSVP, Human Resources · 57 transactions | — | 27.3Kas of Feb 2013 | 153.6K | — | 138.0K |
| Winger Dennis LDirector · 4 transactions | — | 25.3Kas of Mar 2012 | 38.8K | 6.5K | — |
| Liu JoyEVP and Chief Legal Officer · 36 transactions | — | 20.0K | 8.9K | — | 14.0K |
| Atkinson Edward Morrow IIIEVP, Chief Technical Ops. Off. · 36 transactions | — | 18.4K | 54.0K | — | 25.0K |
| Bozic CarmenEVP and CMO · 66 transactions | — | 15.3K | 144.9K | — | 72.3K |
| Biller JonathanEVP and Chief Legal Officer · 31 transactions | — | 13.7K | 45.0K | — | 17.1K |
| McKechnie DuncanEVP, Chief Commercial Officer · 11 transactions | — | 12.5K | 11.8K | — | 10.0K |
| Graney ThomasChief Financial Officer · 4 transactions | — | 12.4Kas of Oct 2018 | 14.1K | — | 1.9K |
| Ullian ElaineDirector · 53 transactions | — | 12.2Kas of Jun 2018 | 194.4K | 5.0K | 187.2K |
| Cordes EugeneDirector · 4 transactions | — | 12.0Kas of Mar 2011 | — | — | 6.0K |
| Power Johanna MessinaVP & Controller · 120 transactions | — | 11.7Kas of Apr 2008 | 15.5K | — | 10.4K |
| Riley Wayne JosephDirector · 16 transactions | — | 10.4Kas of Mar 2015 | 60.0K | — | 59.6K |
| Silva Paul MSVP & Chief Accounting Officer · 417 transactions | — | 10.1Kas of Mar 2021 | 390.7K | — | 377.7K |
| Brimblecombe Roger WDirector · 40 transactions | — | 10.0Kas of Mar 2010 | 57.5K | — | 57.5K |
| Garber Alan MDirector · 7 transactions | — | 7.3K | 7.3K | — | — |
| Bunnage Mark E.EVP, Chief Scientific Officer · 10 transactions | — | 7.3K | 2.6K | — | 6.3K |
| Ambrose KristenSVP & Chief Accounting Officer · 44 transactions | — | 6.6K | 25.4K | — | 11.4K |
| Kearney Terrence CDirector · 28 transactions | — | 6.5Kas of Aug 2023 | 137.1K | — | 130.6K |
| Carney LloydDirector · 11 transactions | — | 6.3K | 9.8K | — | 2.7K |
| Bhatia Sangeeta N.Director · 85 transactions | — | 4.9K | 63.5K | — | 58.6K |
| McKenzie DianaDirector · 12 transactions | — | 3.4K | 8.6K | — | — |
| Lee YuchunDirector · 190 transactions | — | 3.3Kas of Jan 2023 | 76.9K | — | 73.3K |
| Schneider JenniferDirector · 4 transactions | — | 2.2K | 2.2K | — | — |
| Thornberry NancyDirector · 5 transactions | — | 2.1K | 2.5K | — | — |
| Upadhyay SuketuDirector · 7 transactions | — | 1.6K | 4.5K | — | — |
| Lagarde MichelDirector · 1 transaction | — | 1.1Kas of Oct 2023 | 1.1K | — | — |
| Slater Eve ElizabethDirector · 4 transactions | — | 1.1Kas of May 2007 | 10.0K | 1.1K | 10.0K |
| McGlynn Margaret GDirector · 54 transactions | — | 178as of May 2022 | 133.6K | 1.1K | 125.0K |
| Brandt EricDirector · 3 transactions | — | 0as of Jan 2009 | 27.5K | — | 27.5K |
Select a row to see that insider’s individual transactions. Sum of the holdings confirmed in the 12 months before this insider's last filing. A Form 4 reports a holding per line — held directly, or through a named trust, partnership or foundation, and in each share class separately — never a person’s total. Lines not restated in that time are left out and shown apart: an active filer restates what they still hold, so a line they did not restate is more often an entity since renamed, whose shares a successor line reports too. An amber marker means some were left out.
Net open-market activity over all recorded history: -14.17M shares. Grants, option exercises and tax withholding are excluded — they are compensation mechanics, not decisions to buy or sell.